Tag Archives: PULM

Pulmatrix Inc (NASDAQ:PULM) reported earlier this month that it has picked up an additional patent related to its lead development program – PUR0200 in chronic obstructive pulmonary disease (COPD). It adds to a list of a number of already...

Pulmatrix Inc (NASDAQ:PULM) is one that we have covered on numerous occasions in the past, most recently, as part of this report back at the end of March. Year to date, the company has had a bit of a roller coaster ride. As the year began,...

We like to keep our coverage varied here at Insider Financial, but now and again, markets dictate that we revisit a company almost as soon as we’ve taken a look at it. One such situation just presented itself with development stage biotechnology...

At the end of last month, we highlighted Pulmatrix Inc (NASDAQ:PULM) as being a company to watch during the remainder of the first quarter of 2017. Our thesis was simple – the company had taken a considerable hit heading into the latter half...

In August 2016, Pulmatrix Inc (NASDAQ:PULM) announced that the FDA had granted Orphan Drug designation to one of the company’s development assets, a drug called PUR1900. Pulmatrix’s market capitalization failed to respond to the...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter